Peritoneal /Pleural effusions caused by metastatic cancer

Common adverse reactions-
Transitory radiation sickness, bone marrow depression , pleuritis, peritonitis, nausea,
abdominal cramps,

Radiation damage may occur if accidentaly injected interstitially or into a loculation.

Chromic phosphate P 32 should be used in the presence of ulerative tumors.
Administration should not be made in exposed cavites.or there is evidence of loculation,
unless the extent of loculation is determined.

Special precautions/warnings
Chromic phosphate P32 is for intravascular use.

Interactivity installation - careful intracavitary instillation is required to avoid placing the dose of chromic phosphate P 32 into intrpleural or intraperitonal loculations, bowel lumen or into the body wall

Interstinal fibrosis of necrosis and chronic fibrosis of the body wall have been reported.

Pregnancy- should not be administered to patients who are pregnant , unless the benefits
outweigh the risks.

Lactation- should not be administered to patients who are experiencing  lactation unless the benefits ouweigh the risks.

Children - safety and efficacy in pediatric patients not established.

Indication-
Peritoneal /Pleural effusions caused by metastatic cancer

Dosage

Suggested dosage emolyed in average patient 70kg is -

Intraperitoneal instillation - 370 to 740 mBq   ( 10 to mCi )

Intrapleural instillation- 222 to 444 mBq ( 6 to 12mCi )
 Doses for interstitial use should be based on estimated gram weight of tumor about
 3.7 to 18 MBq /g ( 0.1 to 0.5 mCi )

The patient dose  should be  measured by a suitable radioactivity calibration system
immediately prior to administration

Pregnancy-
Should not be administered to patients who are pregnant , unless the benefits
outweigh the risks.

Lactation-
Should notbe administered to patients who are experiencing  lactation unless the
benefits ouweigh the risks.

Children -

Safety and efficacy in pediatric patients not established.